product name
JNK抑制剂II, JNK Inhibitor II. SP600125, CAS 129-56-6, is a potent, cell-permeable, selective, and ATP competitive inhibitor of c-Jun N-terminal kinase (JNK; IC₅₀ = 40 nM for JNK-1 & JNK-2 & 90 nM for JNK-3).
质量水平
检测方案
≥98% (HPLC)
形式
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
yellow-orange
溶解性
DMSO: 15 mg/mL
运输
ambient
储存温度
−20°C
InChI
1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)
InChI key
ACPOUJIDANTYHO-UHFFFAOYSA-N
一般描述
一种有效的，细胞可渗透的，选择性并可逆的c-Jun N末端激酶（JNK）抑制剂（JNK-1和JNK-2的IC50 = 40 nM，JNK-3的IC50=90 nM）。这种抑制对于ATP具有竞争性。与ERK1和p38-2 MAP激酶相比，对JNK的选择性高300倍以上。抑制c-Jun的磷酸化，阻断IL-2、IFN-γ、TNF-α、COX-2的细胞表达。阻断IL-1诱导的磷酸化-Jun积累和c-Jun转录的诱导。也可使用50 mM（5 mg/454 µl）JNK抑制剂II（目录号420128）的DMSO溶液。
一种有效的，细胞可渗透的，选择性并可逆的c-Jun N末端激酶（JNK）抑制剂（JNK-1和JNK-2的IC50 = 40 nM，JNK-3的IC50=90 nM）。这种抑制对于ATP具有竞争性。与ERK1和p38-2 MAP激酶相比，对JNK的选择性高300倍以上。抑制c-Jun的磷酸化，阻断IL-2、IFN-γ、TNF-α、COX-2的细胞表达。阻断IL-1诱导的磷酸化-Jun积累和c-Jun转录的诱导。
生化/生理作用
主要靶标
JNK 1，JNK 2，JNK 3
JNK 1，JNK 2，JNK 3
产物与ATP竞争。
可逆性：是
细胞可渗透性：是
靶标IC50：40 nM，对于JNK-1和JNK-2；90 nM，对于JNK-3
包装
用惰性气体包装
警告
毒性：标准处理（A）
制备说明
对于每10 µM浓度的JNK抑制剂II，在培养基中应包含0.1%DMSO。培养基的预热和向培养基中添加BSA可能会增强其溶解度。
重悬
复溶后，等分并在-20°C下冷冻保存。储备溶液在-20°C下可稳定保存2个月。
其他说明
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Hu Xu et al.
American journal of physiology. Heart and circulatory physiology, 300(3), H913-H921 (2010-12-28)
High-mobility group box 1 (HMGB1) is a nuclear protein that has been implicated in the myocardial inflammation and injury induced by ischemia-reperfusion (I/R). The purpose of the present study was to assess the role of HMGB1 in myocardial apoptosis induced
Dai-Xu Li et al.
General physiology and biophysics, 39(6), 545-555 (2020-11-24)
Cardiovascular disease (CVD) states are associated with endothelial dysfunction (ED) and increased production of ROS in endothelial cells. The present study aimed to explore the protective effects of antioxidant protein peroxiredoxin 6 (PRDX6) on angiotensin II (AngII)‑induced human umbilical vein
Wenjuan Sun et al.
Frontiers in pharmacology, 13, 807452-807452 (2022-05-03)
Inflammation and apoptosis are the major contributors to the mechanisms of acute kidney injury (AKI) due to renal ischemia-reperfusion injury (IRI). Maslinic acid (MA), a pentacyclic triterpene acid mostly found in dietary plants, the current study was to demonstrate the
Kaiyuan Wang et al.
The Journal of clinical investigation, 130(7), 3603-3620 (2020-06-03)
Emerging immune therapy, such as with the anti-programmed cell death-1 (anti-PD-1) monoclonal antibody nivolumab, has shown efficacy in tumor suppression. Patients with terminal cancer suffer from cancer pain as a result of bone metastasis and bone destruction, but how PD-1
Jia He et al.
Frontiers in immunology, 12, 760138-760138 (2022-01-25)
Idiopathic pulmonary fibrosis (IPF) is a group of chronic interstitial pulmonary diseases characterized by an inexorable decline in lung function with limited treatment options. The abnormal expression of transforming growth factor-β (TGF-β) in profibrotic macrophages is linked to severe pulmonary
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门